Giancarlo Agnelli

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10426055/giancarlo-agnelli-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181 33,748 327 73 h-index g-index citations papers 6.88 39,006 8.3 346 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
327	Contemporary clinical management of acute pulmonary embolism: the COPE study <i>Internal and Emergency Medicine</i> , 2022 , 1	3.7	O
326	Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study <i>Stroke</i> , 2022 , STROKEAHA121036695	6.7	2
325	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study <i>European Journal of Cancer</i> , 2022 , 165, 136-145	7.5	1
324	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study <i>Stroke</i> , 2022 , 101161STROKEAHA121038239	6.7	1
323	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. <i>Annals of Neurology</i> , 2021 ,	9.4	3
322	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. <i>Thrombosis Research</i> , 2021 , 208, 138-144	8.2	Ο
321	The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021 , 94, 45-55	3.9	Ο
320	Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 987-993	3.9	2
319	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 700-702	7	
318	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021 , 52, 1450-1454	6.7	2
317	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. <i>European Journal of Cancer</i> , 2021 , 148, 371-381	7.5	15
316	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021 , 96, 102190	14.4	3
315	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. European Journal of Internal Medicine, 2021, 88, 43-51	3.9	1
314	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 3190-3199	9.5	13
313	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2751-2759	15.4	4
312	SMASH-U classification: a tool for aetiology-oriented management of patients with acute haemorrhagic stroke. <i>Internal and Emergency Medicine</i> , 2021 , 16, 109-114	3.7	4
311	Safety of catheter ablation of atrial fibrillation in cancer survivors. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021 , 60, 419-426	2.4	2

310	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. <i>Clinical Drug Investigation</i> , 2021 , 41, 43-51	3.2	5
309	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 616-624	4 7	21
308	Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials. <i>International Journal of Stroke</i> , 2021 , 16, 43-54	6.3	3
307	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021 , 5, e376-e386	2.7	7
306	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2801-2813	15.4	1
305	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	5
304	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 1420-1429	8	7
303	Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021 , 339, 158-163	3.2	3
302	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
301	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102280	14.4	2
300	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1128-1136	7	43
299	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. <i>Cerebrovascular Diseases Extra</i> , 2020 , 10, 44-49	2.1	2
298	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 692-701	7	3
297	Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis. <i>Neurological Sciences</i> , 2020 , 41, 2503-2509	3.5	3
296	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 1599-1607	59.2	320
295	Prognostic value of respiratory index in haemodynamically stable patients with acute pulmonary embolism: The Respiratory Index model study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 286-292	4.3	5
294	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020 , 51, 2347-2354	6.7	5
293	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. <i>European Journal of Internal Medicine</i> , 2020 , 75, 35-43	3.9	13

292	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
291	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020 , 111, 370-372	2.2	
290	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020 , 14, 998	2.7	2
289	Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. <i>International Journal of Cardiology</i> , 2020 , 301, 167-172	3.2	11
288	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. <i>European Journal of Internal Medicine</i> , 2020 , 72, 53-59	3.9	2
287	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020 , 82, 48-55	3.9	4
286	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3´months. <i>Thrombosis Research</i> , 2020 , 196, 297-304	8.2	2
285	Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management. <i>European Journal of Internal Medicine</i> , 2020 , 82, 18-20	3.9	3
284	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020 , 51, 3504-3513	6.7	22
283	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2020 , 83, 566-575	2.1	1
282	A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke. <i>European Stroke Journal</i> , 2020 , 5, 384-393	5.6	3
281	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020 , 5, 374-3	8 § 3	1
280	Definition of major bleeding: Prognostic classification. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2852-2860	15.4	4
279	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S123-S127	8.2	O
278	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology,the</i> , 2020 , 7, e746-e755	14.6	8
277	Diagnosis and Treatment of Deep Vein Thrombosis in the Emergency Department: Results of an Italian Nominal Group Technique Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 10760296	5 2 6959	720
276	Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. Haematologica, 2020 , 105, 838-848	6.6	11
275	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 251-258	5.1	9

(2019-2020)

274	Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. <i>Internal and Emergency Medicine</i> , 2020 , 15, 429-436	3.7	6
273	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <i>Atherosclerosis</i> , 2020 , 293, 94-100	3.1	37
272	Acute treatment of venous thromboembolism. <i>Blood</i> , 2020 , 135, 305-316	2.2	12
271	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 ,	17.2	5
270	The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019 , 42, 1147-1154	3.3	8
269	Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. <i>International Journal of Cardiology</i> , 2019 , 281, 56-61	3.2	18
268	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1694-1706	15.4	17
267	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2093-2100	6.7	17
266	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019 , 50, 2168-2174	6.7	31
265	Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1217-1228	15.4	14
264	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 439-453	5.1	12
263	Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation. <i>Data in Brief</i> , 2019 , 23, 103794	1.2	1
262	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. <i>Quality of Life Research</i> , 2019 , 28, 2111-2124	3.7	15
261	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. <i>Annals of Neurology</i> , 2019 , 85, 823-834	9.4	58
260	Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the <code>Qetter</code> to the EditorOfrom Dr. Sorigue et al. <i>International Journal of Cardiology</i> , 2019 , 280, 97	3.2	
259	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
258	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019 , 4, 55-64	5.6	2
257	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ, The</i> , 2019 , 366, l4363	5.9	83

256	Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study. <i>TH Open</i> , 2019 , 3, e157-e164	2.7	1
255	Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 2043-2052	7	2
254	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. <i>European Journal of Internal Medicine</i> , 2019 , 69, 1-7	3.9	2
253	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
252	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 461-466	7	9
251	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. <i>Quality of Life Research</i> , 2019 , 28, 1155-1177	3.7	5
250	Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. <i>Atherosclerosis</i> , 2018 , 271, 177-181	3.1	14
249	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018 , 170, 181-191	8.2	16
248	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2018 , 29, 391-394	1	1
247	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018 , 16, 9	5.6	11
246	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S168-S171	8.2	O
245	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. <i>Thrombosis Research</i> , 2018 , 165, 33-37	8.2	24
244	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018 , 39, 4208-4218	9.5	156
243	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018 , 23, 247-255	5.7	42
242	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018 , 269, 75-79	3.2	3
241	Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. <i>International Journal of Cardiology</i> , 2018 , 269, 152-157	3.2	22
240	The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach. <i>PLoS ONE</i> , 2018 , 13, e0195805	3.7	6
239	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1668-1678	7	80

238	Alcohol intake and the risk of intracerebral hemorrhage in the elderly: The MUCH-Italy. <i>Neurology</i> , 2018 , 91, e227-e235	6.5	17
237	Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. <i>Blood Transfusion</i> , 2018 , 16, 387-391	3.6	8
236	Bedside sonography assessment of extravascular lung water increase after major pulmonary resection in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018 , 10, 4077-4084	2.6	8
235	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018 , 7, e010133	6	35
234	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 1063-1069	4.1	4
233	The impact of co-morbidity on the disease burden of VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 507-515	5.1	5
232	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. <i>Thrombosis Research</i> , 2018 , 170, 175-180	8.2	21
231	Clinical skills or high-tech MR in TIA patients: what makes the difference?. <i>Neurological Sciences</i> , 2018 , 39, 2091-2096	3.5	2
230	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	6
229	Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2017 , 236, 363-369	3.2	20
228	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017 , 34, 620-637	4.1	6
227	Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 94-106	3.9	2
226	Prestroke CHADS-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 1363-1368	2.8	5
225	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study. <i>Stroke</i> , 2017 , 48, 726-732	6.7	28
224	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation). European Stroke Journal,	5.6	2
223	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. <i>ESMO Open</i> , 2017 , 2, e000188	6	23
222	Risk of death in patients with major bleedings while on treatment with oral anticoagulants. <i>International Journal of Cardiology</i> , 2017 , 235, 200	3.2	
221	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017 , 227, 261-266	3.2	39

220	The year in cardiology 2016: peripheral circulation. European Heart Journal, 2017, 38, 1028-1033	9.5	4
219	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, 16950	3	5
218	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017 , 1, pkx009	4.6	2
217	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 527-535	5.1	8
216	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1291-1305	3.7	14
215	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. <i>Thrombosis Research</i> , 2017 , 157, 181-188	8.2	8
214	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	60
213	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). <i>Circulation</i> , 2017 , 136, 907-9	16.7 9 16	22
212	The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1326-1337	7	58
211	Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes. <i>Internal and Emergency Medicine</i> , 2017 , 12, 573-576	3.7	1
21 0	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. <i>Internal and Emergency Medicine</i> , 2016 , 11, 1095-1102	3.7	5
209	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 410-6	7	31
208	Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 349-55	7	22
207	Reply to Letter: "A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". <i>Annals of Surgery</i> , 2016 , 263, e63	₃ 7.8	1
206	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT: Systematic Review and Meta-analysis. <i>Chest</i> , 2016 , 149, 192-200	5.3	55
205	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 32-67	5.1	167
204	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016 , 263, 231-237	5.5	27
203	Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016 , 128, 1422-1422	2.2	1

(2015-2016)

202	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 809-16	7	13
201	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1159-1164	7	14
200	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. <i>European Journal of Internal Medicine</i> , 2016 , 33, 42-6	3.9	14
199	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 924-9	5.5	22
198	Risk stratification and management of acute pulmonary embolism. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 404-412	3.1	17
197	Treatment of Venous Thromboembolism With New Anticoagulant Agents. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1941-55	15.1	48
196	Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 336-9	5.1	12
195	Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?. <i>Internal and Emergency Medicine</i> , 2016 , 11, 817-24	3.7	7
194	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2016 , 48, 780-6	13.6	140
193	Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. <i>European Respiratory Journal</i> , 2015 , 45, 1142-9	13.6	13
192	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. <i>Stroke</i> , 2015 , 46, 2175-82	6.7	157
191	Thromboprophylaxis with low-molecular-weight heparins: an assessment of the methodological quality of studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 113-32	5.3	7
190	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15006	51.1	127
189	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. <i>Internal and Emergency Medicine</i> , 2015 , 10, 595-601	3.7	9
188	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2015 , 10, 555-60	3.7	9
187	Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2015 , 10, 651-6	3.7	13
186	Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. <i>Thrombosis Research</i> , 2015 , 136, 924-7	8.2	27
185	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. <i>Journal of Neurology</i> , 2015 , 262, 459-68	5.5	33

184	The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry. <i>Thrombosis Journal</i> , 2015 , 13, 41	5.6	35
183	Reply to Letter: "A Randomized Study on 1-week Versus 4-week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". <i>Annals of Surgery</i> , 2015 , 262, e12	23-4	1
182	Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. <i>Chest</i> , 2015 , 147, 475-483	5.3	219
181	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Haematologica</i> , 2015 , 100, e35-8	6.6	20
180	Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No. <i>Internal and Emergency Medicine</i> , 2015 , 10, 281-4	3.7	1
179	Gull de prlitica clilica de la ESC 2014 sobre el diagnilitico y el tratamiento de la embolia pulmonar aguda. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 64.e1-64.e45	1.5	6
178	96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. <i>Internal and Emergency Medicine</i> , 2014 , 9, 65-7	3.7	25
177	Aspirin for prevention and treatment of venous thromboembolism. <i>Blood Reviews</i> , 2014 , 28, 103-8	11.1	35
176	Edoxaban: a focused review of its clinical pharmacology. European Heart Journal, 2014, 35, 1844-55	9.5	90
175	Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. <i>International Journal of Cardiology</i> , 2014 , 177, 601-3	3.2	12
174	Neuroimaging in intracerebral hemorrhage. <i>Stroke</i> , 2014 , 45, 903-8	6.7	75
173	Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i> , 2014 , 130, 1062-71	16.7	190
172	Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. <i>European Respiratory Journal</i> , 2014 , 43, 1678-90	13.6	114
171	Thromboprophylaxis in acutely ill medical patients: results of a survey among Italian physicians. <i>Thrombosis Research</i> , 2014 , 134, 572-7	8.2	2
170	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
169	Fibrinolysis for patients with intermediate-risk pulmonary embolism. <i>New England Journal of Medicine</i> , 2014 , 370, 1402-11	59.2	852
168	New strategies of VTE prevention in cancer patients. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S128-32	8.2	7
167	The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?. <i>Blood</i> , 2014 , 124, 155-6	2.2	15

166	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014 , 9, 559-67	3.7	23
165	Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. <i>Neurology</i> , 2014 , 82, 529-35	6.5	26
164	Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. <i>Thrombosis Research</i> , 2014 , 134, 1265-71	8.2	37
163	Acute stroke symptoms: do differences exist between sexes?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014 , 23, 2928-2933	2.8	10
162	A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Annals of Surgery</i> , 2014 , 259, 665-9	7.8	119
161	Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. <i>Annals of Surgery</i> , 2014 , 259, 1073-9	7.8	20
160	Lung ultrasound in the diagnosis of stroke-associated pneumonia. <i>Internal and Emergency Medicine</i> , 2014 , 9, 173-8	3.7	13
159	New oral anticoagulants for the treatment of venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 151-61	4.2	16
158	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013 , 8, 575-80	3.7	8
157	Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: independent predictors of poor outcome at three months. <i>European Journal of Internal Medicine</i> , 2013 , 24, 310-3	3.9	18
156	Apixaban for extended treatment of venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 368, 699-708	59.2	882
155	Oral apixaban for the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 369, 799-808	59.2	1495
154	Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. <i>Stroke</i> , 2013 , 44, 1584-9	6.7	33
153	Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 471-7	3.1	18
152	Acute pulmonary embolism: external validation of an integrated risk stratification model. <i>Chest</i> , 2013 , 144, 1539-1545	5.3	53
151	Symptoms and clinical relevance: a dilemma for clinical trials on prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 585-8	7	9
150	Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. <i>Journal of Diabetes and Its Complications</i> , 2012 , 26, 70-6	3.2	19
149	D-dimer for risk stratification in patients with acute pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 33, 48-57	5.1	53

148	Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. <i>Journal of Neurology</i> , 2012 , 259, 106-10	5.5	26
147	New and old anticoagulants in cancer. <i>Thrombosis Research</i> , 2012 , 129 Suppl 1, S101-5	8.2	13
146	Admission leukocytosis in acute cerebral ischemia: influence on early outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 819-24	2.8	33
145	Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 601-9	59.2	405
144	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Pilluci che ombre. <i>Italian Journal of Medicine</i> , 2012 , 6, 153-169	0.5	
143	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. <i>Thrombosis Research</i> , 2012 , 129, 392-400	8.2	49
142	Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. <i>Thrombosis Research</i> , 2012 , 130, 369-73	8.2	25
141	Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). <i>Thrombosis Research</i> , 2012 , 130, 847-52	8.2	82
140	Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study. <i>Cerebrovascular Diseases</i> , 2012 , 34, 430-5	3.2	20
139	Aspirin for preventing the recurrence of venous thromboembolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1959-67	59.2	444
138	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Internal and Emergency Medicine</i> , 2012 , 7, 291-2	3.7	231
137	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1287-97	59.2	1692
136	Systemic thrombolysis in patients with acute ischemic stroke and Internal Carotid ARtery Occlusion: the ICARO study. <i>Stroke</i> , 2012 , 43, 125-30	6.7	74
135	Multidetector CT scan for acute pulmonary embolism: embolic burden and clinical outcome. <i>Chest</i> , 2012 , 142, 1417-1424	5.3	75
134	Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 672	0.8	
133	Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical Pharmacokinetics, 2011, 50, 675-86	6.2	239
132	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants and from seven trials. <i>BMJ, The</i> , 2011 , 342, d3036	5.9	234
131	Non-neurological complications of acute stroke: frequency and influence on clinical outcome. Internal and Emergency Medicine, 2011, 6 Suppl 1, 119-23	3.7	17

(2009-2011)

130	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> , 2011 , 9, 179	8.5	75
129	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. <i>European Heart Journal</i> , 2011 , 32, 1657-63	9.5	153
128	Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovascular Diseases, 2011, 31, 109-16	3.2	41
127	New anticoagulants for the prevention of venous thromboembolism. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 49-60	4.4	20
126	Gender differences in patients with acute ischemic stroke. Womenm Health, 2010, 6, 51-7	3	38
125	Acute pulmonary embolism. New England Journal of Medicine, 2010, 363, 266-74	59.2	337
124	Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. <i>Thrombosis Research</i> , 2010 , 125, e82-6	8.2	134
123	Thromboprophylaxis during chemotherapy in patients with advanced cancer. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S17-20	8.2	10
122	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. <i>Atherosclerosis</i> , 2010 , 212, 564-6	3.1	28
121	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2010 , 363, 2499-510	59.2	2240
121		59.2 3·7	2240
	2010, 363, 2499-510 Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i>		
120	2010, 363, 2499-510 Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010, 5, 281-90 Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> ,	3.7	14
120	 2010, 363, 2499-510 Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i>, 2010, 5, 281-90 Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i>, 2010, 5, 453-5 Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular</i> 	3.7	14
120 119 118	Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010, 5, 281-90 Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2010, 5, 453-5 Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular Diseases</i> , 2009, 28, 119-23 The concept of ischemic penumbra in acute stroke and therapeutic opportunities. <i>European</i>	3·7 3·7 3·2	14 10 54
120 119 118	 2010, 363, 2499-510 Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i>, 2010, 5, 281-90 Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i>, 2010, 5, 453-5 Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular Diseases</i>, 2009, 28, 119-23 The concept of ischemic penumbra in acute stroke and therapeutic opportunities. <i>European Neurology</i>, 2009, 61, 321-30 Seasonal variation in the occurrence of venous thromboembolism: data from the MASTER Registry. 	3·7 3·2 2.1	14 10 54 96
120 119 118 117 116	Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010, 5, 281-90 Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2010, 5, 453-5 Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular Diseases</i> , 2009, 28, 119-23 The concept of ischemic penumbra in acute stroke and therapeutic opportunities. <i>European Neurology</i> , 2009, 61, 321-30 Seasonal variation in the occurrence of venous thromboembolism: data from the MASTER Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 309-15 Low levels of low-density lipoprotein cholesterol increase hemorrhagic transformation but not	3.7 3.2 2.1 3.3	14 10 54 96 25

112	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology, The</i> , 2009 , 10, 943-9	21.7	443
111	Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. <i>Annals of Internal Medicine</i> , 2009 , 150, 577-85	8	162
110	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 596-598	7	5
109	Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 454S-545S	5.3	1562
108	The MASTER registry on venous thromboembolism: description of the study cohort. <i>Thrombosis Research</i> , 2008 , 121, 605-10	8.2	62
107	Clinical benefit of early anticoagulation in cardioembolic stroke. <i>Cerebrovascular Diseases</i> , 2008 , 25, 289)- <u>9.6</u>	10
106	Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. <i>Cerebrovascular Diseases</i> , 2008 , 25, 129-35	3.2	51
105	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008 , 93, 273-8	6.6	99
104	Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins. <i>Expert Review of Molecular Diagnostics</i> , 2008 , 8, 339-49	3.8	11
103	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. <i>Blood</i> , 2008 , 112, 2242-7	2.2	275
102	Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. <i>Stroke</i> , 2008 , 39, 2249-56	6.7	334
101	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 663-7	1	19
100	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 978-80	7	11
99	A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 241-4	7	14
98	Treatment of DVT: how long is enough and how do you predict recurrence. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 25, 37-44	5.1	49
97	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. <i>Internal and Emergency Medicine</i> , 2008 , 3, 117-22	3.7	87
96	Need for extensive diagnostic work-up for patients with lacunar stroke. <i>Journal of Neurology</i> , 2008 , 255, 637-42	5.5	16
95	Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Heart Journal, 2008, 29, 2276-315	9.5	2125

(2007-2008)

94	Epidemiology of cerebral vein and sinus thrombosis. <i>Frontiers of Neurology and Neuroscience</i> , 2008 , 23, 16-22	1.1	23
93	A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study. <i>Blood</i> , 2008 , 112, 6-6	2.2	17
92	Statins and stroke prevention. <i>Cerebrovascular Diseases</i> , 2007 , 24, 170-82	3.2	55
91	The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. <i>Journal of Surgical Oncology</i> , 2007 , 96, 265-72	2.8	16
90	Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. <i>European Urology</i> , 2007 , 51, 130-5; discussion 136	10.2	44
89	Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. <i>Cerebrovascular Diseases</i> , 2007 , 24, 215-8	3.2	40
88	Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. <i>Circulation</i> , 2007 , 116, 180-7	16.7	289
87	Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> , 2007 , 38, 423-30	6.7	223
86	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007 , 92, 812-8	6.6	80
85	Venous thromboembolism (VTE) in Europe. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 756-764	7	895
84	What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?. <i>Thrombosis Research</i> , 2007 , 119, 265-74	8.2	65
83	Thromboprophylaxis during chemotherapy after advanced cancer. <i>Thrombosis Research</i> , 2007 , 120 Suppl 2, S128-32	8.2	6
82	Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. <i>Circulation</i> , 2007 , 116, 427	7-36 3.7	506
81	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007 , 28, 1717-22	9.5	103
80	Vitamin K Antagonists and Novel Oral Anticoagulant 2007 , 175-184		
79	Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. <i>Vascular Health and Risk Management</i> , 2007 , 3, 749-54	4.4	12
78	Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement <i>Blood</i> , 2007 , 110, 309-309	2.2	1
77	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 756-64	7	430

76	Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006 , 35, 428-34		5
75	New anticoagulants. Seminars in Thrombosis and Hemostasis, 2006, 32, 793-802	5.3	11
74	Therapy Insight: venous-catheter-related thrombosis in cancer patients. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 214-22		40
73	Initial treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 242-50	7	9
72	Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. <i>Chest</i> , 2006 , 130, 172-5	5.3	313
71	Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. <i>Archives of Internal Medicine</i> , 2006 , 166, 2151-6		7 ²
70	A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. <i>Annals of Surgery</i> , 2006 , 243, 89-95	7.8	469
69	Current issues in anticoagulation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005 , 34 Suppl 1, 2-9		18
68	A prospective study on cardiovascular events after acute pulmonary embolism. <i>European Heart Journal</i> , 2005 , 26, 77-83	9.5	135
67	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. <i>Thrombosis Research</i> , 2005 , 116, 301-6	8.2	42
66	Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery: Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety. <i>Clinical Drug Investigation</i> ,	3.2	15
65	2005, 25, 65-77 Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005, 129, 811-7	4.5	113
64	Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. <i>Current Pharmaceutical Design</i> , 2005 , 11, 3885-91	3.3	9
63	Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4057-62	2.2	261
62	Outcome in patients with stroke associated with internal carotid artery occlusion. <i>Cerebrovascular Diseases</i> , 2005 , 20, 108-13	3.2	68
61	A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR <i>Blood</i> , 2005 , 106, 278-278	2.2	11
60	Thrombosis and cancer: clinical relevance of a dangerous liaison. <i>Haematologica</i> , 2005 , 90, 154-6	6.6	11
59	Long-term therapy of pulmonary embolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005 , 6, 824-9		

(2001-2004)

58	Recurrent venous thromboembolism in men and women. <i>New England Journal of Medicine</i> , 2004 , 351, 2015-8; author reply 2015-8	59.2	25
57	Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2004 , 126, 401S-428S	5.3	1000
56	Prevention of venous thromboembolism in surgical patients. Circulation, 2004, 110, IV4-12	16.7	160
55	Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. <i>Drugs</i> , 2004 , 64 Suppl 1, 47-52	12.1	6
54	Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. <i>Circulation</i> , 2004 , 110, 744-9	16.7	451
53	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 288-296	7	221
52	Duration of anticoagulant treatment after venous thromboembolism. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003 , 33, 354-7		
51	Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3665-75	2.2	448
50	Extended oral anticoagulant therapy after a first episode of pulmonary embolism. <i>Annals of Internal Medicine</i> , 2003 , 139, 19-25	8	261
49	Critical issues in peripheral arterial disease detection and management: a call to action. <i>Archives of Internal Medicine</i> , 2003 , 163, 884-92		398
48	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 288-96	7	38
47	Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 947-952	7	60
46	Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. <i>Archives of Internal Medicine</i> , 2002 , 162, 2537-41		87
45	Unresolved issues in the prevention and treatment of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2002 , 28 Suppl 2, 33-40	5.3	1
44	Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. <i>New England Journal of Medicine</i> , 2002 , 346, 975-80	59.2	799
43	Novel approaches to the treatment of thrombosis. <i>Trends in Pharmacological Sciences</i> , 2002 , 23, 25-32	13.2	63
42	Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. <i>Haematologica</i> , 2002 , 87, 757-70	6.6	12
41	Antithrombotic therapy for venous thromboembolic disease. <i>Chest</i> , 2001 , 119, 176S-193S	5.3	439

40	Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. <i>Circulation</i> , 2001 , 104, 74-8	16.7	155
39	End points in studies on the prevention of deep vein thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2001 , 27, 41-6	5.3	3
38	Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. <i>New England Journal of Medicine</i> , 2001 , 345, 165-9	59.2	467
37	Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. <i>Seminars in Hematology</i> , 2001 , 38, 58-66	4	9
36	Risk factors for adverse short-term outcome in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2001 , 103, V239-44	8.2	16
35	Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. <i>Archives of Internal Medicine</i> , 2000 , 160, 2327-32		173
34	Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. <i>Circulation</i> , 2000 , 101, 2817-22	16.7	648
33	Prevention of venous thromboembolism. <i>Thrombosis Research</i> , 2000 , 97, V49-62	8.2	33
32	Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 30-34	7	59
31	Dermatan sulphate in patients with heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1999 , 104, 87-9	4.5	9
30	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. <i>American Journal of Cardiology</i> , 1998 , 82, 1230-	53	84
29	Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. <i>New England Journal of Medicine</i> , 1998 , 339, 80-5	59.2	432
28	Antithrombotic therapy for venous thromboembolic disease. <i>Chest</i> , 1998 , 114, 561S-578S	5.3	170
27	Pharmacokinetic optimisation of the treatment of deep vein thrombosis. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 145-72	6.2	10
26	Venous Thromboembolism and Gancer: a Two-Way Clinical Association. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 117-120	7	40
25	Experimental Pharmacology of Hirunorm: a Novel Synthetic Peptide Thrombin Inhibitor. <i>Thrombosis and Haemostasis</i> , 1996 , 76, 384-392	7	8
24	Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. <i>Thrombosis and Haemostasis</i> , 1996 , 76, 0887-0892	7	32
23	Non-Anticoagulant Actions of Glycosaminoglycans 1996 , 101-112		

22	Anticoagulation in the prevention and treatment of pulmonary embolism. <i>Chest</i> , 1995 , 107, 39S-44S	5.3	12
21	Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. <i>International Journal of Cardiology</i> , 1995 , 49 Suppl, S77-87	3.2	3
20	Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. <i>Circulation</i> , 1995 , 92, 2819-24	16.7	27
19	Clinical Outcome of Orthopaedic Patients with Negative Lower Limb Venography at Discharge. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 1042-1044	7	13
18	Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. <i>Chest</i> , 1994 , 106, 718-24	5.3	154
17	Plasma thrombin neutralization assay: pharmacokinetic applications. <i>Seminars in Thrombosis and Hemostasis</i> , 1994 , 20, 266-73	5.3	3
16	Dermatan sulphate in heparin-induced thrombocytopenia. <i>Lancet, The</i> , 1994 , 344, 1295-6	40	22
15	New strategies for enhancing the speed and rate of coronary reperfusion. <i>American Journal of Cardiology</i> , 1993 , 72, 51G-58G	3	1
14	Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935). <i>Thrombosis and Haemostasis</i> , 1993 , 70, 294-300	7	13
13	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 443-447	7	6
13		<i>7 5.</i> 3	20
	Thrombosis and Haemostasis, 1993 , 70, 443-447		
12	Thrombosis and Haemostasis, 1993, 70, 443-447 Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172S-182S PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of	5.3	20
12	Thrombosis and Haemostasis, 1993, 70, 443-447 Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172S-182S PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-6 A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of	5-3	20
12 11 10	Thrombosis and Haemostasis, 1993, 70, 443-447 Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172S-182S PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-6 A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. Thrombosis and Haemostasis, 1992, 67, 203-208 Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip	5·3 15.1	20 284 82
12 11 10	Thrombosis and Haemostasis, 1993, 70, 443-447 Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172S-182S PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-6 A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. Thrombosis and Haemostasis, 1992, 67, 203-208 Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients. Thrombosis and Haemostasis, 1992, 68, 257-260	5·3 15.1 7	20 284 82 23
12 11 10 9 8	Thrombosis and Haemostasis, 1993, 70, 443-447 Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172S-182S PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-6 A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. Thrombosis and Haemostasis, 1992, 67, 203-208 Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients. Thrombosis and Haemostasis, 1992, 68, 257-260 Rationale for bolus t-PA therapy to improve efficacy and safety. Chest, 1990, 97, 1615-167S The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus	5·3 15·1 7 7 5·3	20 284 82 23 46

4	Desmopressin-induced improvement of abnormal coagulation in chronic liver disease. <i>Lancet, The</i> , 1983 , 1, 645	40	20
3	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. <i>Thrombosis and Haemostasis</i> , 1981 , 46, 572-572	7	8
2	Factor-VIIcoag kinetics in factor-VII-CRM+ and factor-VII-CRM-deficiencies. <i>British Journal of Haematology</i> , 1980 , 46, 307-9	4.5	2
1	Thrombolysis for the Treatment of Pulmonary Embolism503-512		